Ro Pharmacy vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
NY digital health platform with owned pharmacy at $350M revenue in men's health, women's health, and GLP-1 weight management; $876M raised competing with Hims & Hers for DTC telehealth prescription delivery.
About
Ro is a New York-based digital health platform — backed with $876 million raised from General Catalyst, SignalFire, L Catterton, and others at a peak $7 billion valuation — providing telemedicine consultations, prescription management, and pharmacy-grade medication delivery for men's health (erectile dysfunction, hair loss under the Roman brand), women's health (fertility, menopause under the Rory brand), primary care (Ro Primary Care), and weight management (body program with GLP-1 medications). Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, Ro generated approximately $350 million in revenue in 2024, serving over 2 million patients who have completed consultations through its platforms.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.